Home
overview

Set to double from $32bn to $64bn over the next 15 years, the global diabetes market is set for stellar growth as changing demographics and new therapies begin entering the clinic.

Diabetes is now at epidemic levels and will account for eight percent of the world’s adult population by 2030. As the number of diabetics grows, so will the need for new treatments to mitigate the effects on the vasculature and renal system. In a vicious cycle, diabetics have four times the rate of heart disease as non-diabetics, while those with kidney problems are up to 100 times more susceptible to heart attacks and stroke than non-diabetics. With up to 50 million people currently affected by diabetic heart disease and 100 million forecast by 2025, more effective therapeutics are desperately needed. 

Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.  

  • Receive clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors
  • Utilise biomarkers and imaging for the development of novel therapies for diabetes
  • Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes
  • Remain abreast of new EU and FDA guidelines on clinical trials on risk-benefit assessment
  • Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors
  • Review clinical results from the DEMAND study

Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Principal Investigators,Managers, Project/Team Leaders in:

• Diabetes & Obesity, Clinical R&D

• Renal and Kidney Diseases

• Endocrinology and Metabolic Diseases

• Cardiovascular and Gastrointestinal Diseases

• Anti-Diabetic Agents & Advanced Diabetes Systems

• Biomarkers

• Imaging and Translational Medicine

• Drug Development

• Monoclonal Antibodies

• Molecular Neuroscience

• New Products Global Marketing

• Business Development, Licensing & Partnership

• Venture Capital

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Martin Siman

Martin Siman , Director, Design and Interpretation Centre of Excellence , AstraZeneca

9:10 Cardiovascular outcome trials in diabetes- where are we heading?

Arne Ring

Arne Ring, Head of the Statistics and Modelling Group, Diabetes Trials Unit, University Of Oxford

  • The Rosiglitazone story
  • How diabetes guidelines change(d) trial designs for cardiovascular trials
  • Recent examples of trial designs
  • How to conduct these pragmatic trials in an efficient way
  • 9:50 Cardiovascular risk: shifting regulatory perspectives

    John Warren

    John Warren, Director, Medicines Assessment Ltd

  • FDA's response to Vioxx
  • FDA's response to Glitazones
  • FDA's response to obesity drugs
  • Litigation and risk >2
  • EU regulatory position
  • Implications of cardiovascular safety threshold for efficacy assessment
  • 10:30 Morning Coffee

    11:00 Introduction to DPP4 inhibitors

    Haya Langerman

    Haya Langerman, Medical Advisor, Merck Sharp & Dohme Ltd

  • Update on clinical data: Chronic renal insufficiency
  • Cardiovascular properties of incretins
  • Recent data
  • Research questions on incretins
  • 11:40 The legal liabilities risks of inadequately defined risk

    Peter Feldschreiber

    Peter Feldschreiber, Barrister, Four New Square

  • Risk/benefit assessments: clinical prognostic risk, socio-economic and environmental risks, consumer protection, intellectual property, commercial risks and risk of criminal sanctions
  • Risk/benefit profile: current international legislation and regulatory objectives for medicinal products
  • Examples of regulatory failure: Vioxx, Seroxat, the glitazones and TGN1412
  • 12:20 Networking Lunch

    13:20 Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

    Philip Ambery

    Philip Ambery, Director, Clinical Development, GlaxoSmithKline

  • Links between diabetes and CVD
  • Novel diabetes drugs and CVD
  • Future direction
  • 14:00 The kidney as a target for diabetes treatment: from concept to clinical reality

    John Wilding

    John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital

  • Normal renal glucose transport
  • Does altered renal glucose transport contribute to hyperglycaemia in diabetes?
  • Blocking renal glucose transport – theoretical considerations
  • SGLT2 inhibitors as treatment for diabetes: benefits and risks
  • 14:40 Dapagliflozin in subjects with type 2 diabetes

    James F. List

    James F. List, Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb

  • Inhibition of renal glucose re-uptake
  • Effects of urinary glucose excretion on glycaemic control and weight
  • Renal, cardiovascular, and other safety observations
  • 15:20 Afternoon Tea

    15:40 Panel discussion: Assessing endpoints in diabetic cardiovascular complications- where are we and what are the prospects for the future?

  • Glycemic efficacy and safety assessment across various sub-populations
  • Assessment of macrovascular safety and microvascular outcomes
  • What HTAs require from drug developers
  • What is the ideal degree of safety assurance?
  • What is the practical level of safety assurance pre- and post-marketing?
  • James F. List

    James F. List, Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb

    John Warren

    John Warren, Director, Medicines Assessment Ltd

    Arne Ring

    Arne Ring, Head of the Statistics and Modelling Group, Diabetes Trials Unit, University Of Oxford

    John Wilding

    John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital

    Philip Ambery

    Philip Ambery, Director, Clinical Development, GlaxoSmithKline

    16:20 Efficacy and safety of Linagliptin in phase IIIa and IIIb programs and in various sub-populations

    Sanjay Patel

    Sanjay Patel, Global Clinical Development Lead - Diabetes, Boehringer Ingelheim

  • Glycemic efficacy and safety assessment across various sub-populations
  • Assessment of macrovascular safety
  • Assessment of microvascular outcomes
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    Luigi Gnudi

    Luigi Gnudi, Professor of Diabetes and Metabolic Medicine, Honorary Consultant in Diabetes and Endocrinology, Head, Unit for Metabolic Medicine, Cardiovascular Division, Kings College London

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    John Wilding

    John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital

    9:10 Inflammatory cytokines, profibrotic growth factor biomarkers and therapeutic targets in diabetic nephropathy & obesity-related glomerulopathy

    Frederick Tam

    Frederick Tam, Reader in Renal Medicine, Imperial College Of Science Technology & Medicine

  • Diabetic nephropathy is the most common cause of renal failure
  • Obesity is associated with glomerular disease, which may progress to renal failure
  • Urinary cytokines and pro-fibrotic growth factors are non-invasive biomarkers for progression of renal diseases
  • 9:50 Lipotoxicity in type 2 diabetes

    Vera Schrauwen-Hinderling

    Vera Schrauwen-Hinderling, Assistant Professor, University of Maastricht Medical Centre

  • Why does fat accumulate in cardiac muscle?
  • The association between cardiac steatosis and cardiomypoathy in type two diabetes
  • Mechanistic effects of lipoapoptosis
  • 10:30 Morning Coffee

    11:00 Diabetic retinopathy: focus on vascular permeability and oedema

    Patric Turowski

    Patric Turowski, Senior Lecturer, Cell Biology, Institute of Ophthalmology, University College London

  • Clinical manifestations of macular oedema
  • Properties and features of the blood-brain and retinal barriers
  • Mechanisms of VEGF induced vascular permeability
  • Potential role for leukostasis in diabetic retinopathy
  • 11:40 Control of hyperkalemia to extend the benefits of aldosterone blockade in diabetic nephropathy and heart failure

    Jerry  Buysse

    Jerry Buysse, Chief Scientific Officer and Senior Vice President, Research, Relypsa

  • RAAS inhibition represents the cornerstone of therapy that serves to preserve renal function and delay disease progression
  • Despite demonstrated cardio- and renoprotective outcomes in RAAS blockade studies, hyperkalemia associated with RAAS therapy often prevents optimum use of the drugs
  • The novel, high capacity potassium binding polymer, RLY5016, has been developed to prevent and treat hyperkalemia in heart failure and diabetic nephropathy patients, particularly in patients receiving long term RAAS therapy
  • 12:20 Networking Lunch

    13:40 Treatment of diabetic dyslipidemia

    Rebecca Taub

    Rebecca Taub, Chief Executive Officer, Madrigal Pharmaceuticals

  • Dyslipidemia as a leading factor in the formation of atherosclerosis
  • Diabetics in particular have additional risks and therapeutic needs for lipid modifiers
  • Impact of lowering of LDL cholesterol, triglycerides and Lp(a)
  • 3196: a liver-directed thyroid hormone receptor-beta agonist for the treatment of hypercholesterolemia
  • 14:20 An integrated “omics” approach to discover and validate FGF21 target engagement biomarkers

    Sandra Souza

    Sandra Souza, Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme

  • Phosphoproteomic profiling of cultured adipocytes
  • Transcriptomic profiling of mouse adipose tissue; identification of RNA transcripts and secreted proteins
  • In vivo validation of proposed target engagement biomarkers
  • 15:00 Chairman’s Closing Remarks and Close of Day Two

    John Wilding

    John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital

    15:10 Afternoon Tea

    +

    FEATURED SPEAKERS

    James F. List

    James F. List

    Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb
    John Wilding

    John Wilding

    Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital
    Martin Siman

    Martin Siman

    Director, Design and Interpretation Centre of Excellence , AstraZeneca
    Philip Ambery

    Philip Ambery

    Director, Clinical Development, GlaxoSmithKline
    Sandra Souza

    Sandra Souza

    Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme

    Arne Ring

    Head of the Statistics and Modelling Group, Diabetes Trials Unit, University Of Oxford
    Arne Ring

    Frederick Tam

    Reader in Renal Medicine, Imperial College Of Science Technology & Medicine
    Frederick Tam

    Haya Langerman

    Medical Advisor, Merck Sharp & Dohme Ltd
    Haya Langerman

    James F. List

    Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb
    James F. List

    Jerry Buysse

    Chief Scientific Officer and Senior Vice President, Research, Relypsa
    Jerry  Buysse

    John Warren

    Director, Medicines Assessment Ltd
    John Warren

    John Wilding

    Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital
    John Wilding

    Luigi Gnudi

    Professor of Diabetes and Metabolic Medicine, Honorary Consultant in Diabetes and Endocrinology, Head, Unit for Metabolic Medicine, Cardiovascular Division, Kings College London
    Luigi Gnudi

    Martin Siman

    Director, Design and Interpretation Centre of Excellence , AstraZeneca
    Martin Siman

    Patric Turowski

    Senior Lecturer, Cell Biology, Institute of Ophthalmology, University College London
    Patric Turowski

    Peter Feldschreiber

    Barrister, Four New Square
    Peter Feldschreiber

    Philip Ambery

    Director, Clinical Development, GlaxoSmithKline
    Philip Ambery

    Rebecca Taub

    Chief Executive Officer, Madrigal Pharmaceuticals
    Rebecca Taub

    Sandra Souza

    Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme
    Sandra Souza

    Sanjay Patel

    Global Clinical Development Lead - Diabetes, Boehringer Ingelheim
    Sanjay Patel

    Vera Schrauwen-Hinderling

    Assistant Professor, University of Maastricht Medical Centre
    Vera Schrauwen-Hinderling

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.